#Israel #Compugen #Holon #COM503 #SITC 2025

Compugen to Present at SITC 2025

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a leading company specializing in cancer immunotherapy, is set to share significant findings at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland, from November 7 to 9, 2025. The company has gained recognition for its innovative approach leveraging artificial intelligence and machine learning in predictive computational target discovery in the field of oncology.

At this year's conference, Compugen will present interim results from its first-in-human clinical trial examining the anti-IL18BP antibody, known as COM503 (GS-0321). This trial targets patients with advanced solid tumors, wherein the therapeutic candidate aims to enhance the immune response against cancer cells by blocking the IL-18 binding protein.

Presentation Details

The key presentation will take place on November 7, 2025. Dr. Manish Sharma, the Co-Director of Clinical Research at START Midwest in Grand Rapids, will be the lead presenter. He will share insights encapsulated in the abstract titled ‘A First in Human Clinical Trial to Assess the Anti-IL18BP Antibody, COM503 (GS-0321) in Participants with Advanced Solid Malignancies’, which is abstract number 589.

About COM503 and Compugen

COM503 represents a strategic advancement in the development of targeted immunotherapies. It is being explored for its potential to disrupt the IL-18 pathway, which plays a crucial role in tumor progression and immune evasion. This novel therapeutic could pave the way for new treatment modalities that specifically address the unique challenges posed by advanced solid malignancies.

Compugen is currently advancing several novel therapeutic candidates. Beyond COM503, the company is also developing COM701, a potential first-in-class antibody targeting PVRIG, and COM902, which targets TIGIT, both designed to enhance the body's immune response against tumors. Compugen's product pipeline is bolstered by its proprietary technology platform, Unigen™, which is adept at identifying new drug targets and biological pathways, thereby revolutionizing drug discovery.

Industry Significance

The advancements presented at SITC are crucial within the context of a rapidly advancing field of immunotherapy. As more treatment options become available, understanding the mechanisms by which these new therapies operate enables clinicians and researchers to optimize patient outcomes. Compugen’s focus on predictive AI in drug discovery offers the potential to significantly shorten the time frames normally associated with developing effective cancer treatments.

Given the pressing need for innovative therapeutics in cancer care, the findings showcased in this presentation hold promise for clinicians treating advanced malignancies and for researchers looking into the intricacies of tumor immunology.

The Future of Cancer Treatment

As the landscape of cancer treatment continues to evolve, forums like SITC allow for the dissemination of crucial research findings and foster collaboration among industry leaders, enhancing patient care. Compugen’s presence at the conference underlines its commitment to pushing the boundaries of cancer immunotherapy through groundbreaking research and development.

For additional information, potential investors and interested stakeholders can reach out to Dr. Yvonne Naughton, Vice President and Head of Investor Relations at Compugen.

For those unable to attend the conference, updates will be available via Compugen’s official communications and investor relations channels following the event.